Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage I Breast Cancer|Anatomic Stage II Breast Cancer|Anatomic Stage III Breast Cancer|Invasive Breast Lobular Carcinoma
Interventions: PROCEDURE: Endocrine Therapy|PROCEDURE: Biopsy of breast|DRUG: Neratinib|PROCEDURE: Biospecimen Collection|PROCEDURE: Mammogram|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Breast Surgery|PROCEDURE: Ultrasound
Sponsor: Vanderbilt-Ingram Cancer Center
Collaborators: National Cancer Institute (NCI)|Puma Biotechnology, Inc.